AGENDA

Sunday, April 7, 2019

10:00 – 6:30  REGISTRATION [Regency Foyer]

1:00 – 3:00  POSTER SET-UP [Millennium Hall]

3:00 – 3:30  WELCOME AND INTRODUCTION TO THE WORKSHOP [Regency Ballroom]
Workshop Chair: Peter Merkel

3:30 – 4:30  SESSION S1 [Regency Ballroom]
Introductory Remarks
Francis S. Collins, MD, PhD
Fokko Van Der Woude Lecture
Carl June, MD
“CAR-T Cell Therapy in Autoimmune Disease”

4:30 – 5:30  SESSION S2 [Regency Ballroom]
Early Investigators Award-Winning Abstract Presentations
Abstract Presentation and Awards Ceremony
Moderators: Yoshihiro Arimura and Rennie Rhee
1. Jacoba Graver, Leukocyte Dynamics Before, During and After Treatment in Giant Cell Arteritis and Polymyalgia Rheumatica Patients [303]
2. Katherine Gribbons, Discovery and Validation of a Novel Angiographic Classification Scheme in Takayasu’s Arteritis [084]
3. Maria Prendecki, Fostamatinib Treatment of a New Model of MPO-ANCA Vasculitis in WKY Rats Induced by Administration of a Subnephritogenic Dose of Nephrotoxic Serum After Immunisation with Human Myeloperoxidase [212]
4. Limy Wong, Genetic Evidence of Eosinophil Number Underpinning PR3-AAV and Plausible Host Genetic Predisposition to Microbial Drivers of Disease [185]

5:30 – 6:30  SESSION S3 [Regency Ballroom]
New Classification Criteria for Vasculitis: Results from the International DCVAS Study
Moderators: Carol Langford and Shunsuke Furuta
Peter Grayson, Classification Criteria for Large-Vessel Vasculitis [077]
Joanna Robson, Classification Criteria for the ANCA-Associated Vasculitides [110]

7:00 – 10:00  WELCOME RECEPTION
Reading Terminal Market
Monday, April 8, 2019

6:45 AM – 6:00 PM  REGISTRATION  [Regency Foyer]

6:45 – 8:00  CONTINENTAL BREAKFAST AND POSTER SET-UP  [Millennium Hall]

8:00 – 9:20  SESSION M1  [Regency Ballroom]
Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Moderators: David Jayne and Benjamin Terrier

1. Joanna Tieu, Rituximab Associated Hypogammaglobulinaemia in Autoimmune Disease: Long Term Outcomes [356]

2. Reza Zonozi, Late-Onset Neutropenia in Patients Undergoing Rituximab-Induced Continuous B Cell Depletion for Autoimmune Disease: Data from a 739 Patient Cohort and Approach to Management [364]

3. John Niles, Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Rituximab in ANCA-Associated Vasculitis Registry [327]


5. Seerapani Gopaluni, ALEmtuzumab for Relapsing and Refractory Primary Systemic Vasculitis – A Trial of Efficacy and Safety (ALEVIATE): A Randomised Open Label Phase II Clinical Trial [302]

9:30 – 10:20  INVITED SPEAKER  [Regency Ballroom]

Moderator: Peter Merkel

David Fajgenbaum, MD, MBA, MSc
“Personalized, Personalized Medicine”

10:20 – 11:00  BREAK AND POSTER VIEWING  [Millennium Hall]

11:00 – 12:20  BREAKOUTS

SESSION M2A  [Regency Ballroom]
Histopathology and the Diagnosis of Vasculitis

Moderators: Ingeborg Bajema and John Stone

1. Laarni Quimson, Comparison of Aortitis vs Non-Inflammatory Aortic Aneurysms Among Patients Who Undergo Open Aortic Aneurysm Repair [108]

2. Raymond Chu, A Ten-Year Retrospective Review of Temporal Artery Biopsy Lengths in Alberta [133]

3. Emma Rubenstein, Sensitivity of Temporal Artery Biopsy in Giant Cell Arteritis: Systematic Literature Review and Meta-Analysis of Clinical Data [111]

4. Maria Wester Trejo, Differences in Renal Histopathology Between PR3-ANCA-Associated Vasculitis and MPO-ANCA-Associated Vasculitis [120]

5. Antoine Néel, Value of Muscle Biopsy in ANCA-Associated Vasculitis: Diagnostic Yield Depends on ANCA Type [105]

SESSION M2B  [Commonwealth Hall A-D]
Antigen-Specific Immunity: Beyond ANCA

Moderators: Judy Savige and Paul Monach

1. Meghan Free, Critical MPO Epitopes Drive the CD4+ T Cell Response in MPO-ANCA Vasculitis [191]

2. Divi Cornec, Detection of Circulating PR3-Specific B Cells in Patients with Active ANCA-Associated Vasculitis [190]

3. Carolina Herrera, Activation of Neutrophils with MPO-ANCA Correlates with MPO Autoantigen Gene Expression [192]

4. Roberto Padoan, Anti-Pentraxin-3 Autoantibodies in ANCA-Associated Vasculitis [039]

5. Benjamin Wilde, Autoantigen Specific Th17 Cells Inflame the Kidney in ANCA-Vasculitis and Mediate Renal Damage [225]

12:30 – 1:30  SPONSORED LECTURE LUNCH  [Regency Ballroom]

OR LUNCH ON YOUR OWN
Yusuf Yazici, MD
“Exploring the Clinical Understanding of Behçet’s Syndrome”
Monday, April 8, 2019 (continued)

**Session M3A [Commonwealth A-D Hall]**  
**Eosinophilic Granulomatosis with Polyangiitis**  
**Moderators:** Christian Pagnoux and Rona Smith

1. Benjamin Terrier, *Efficacy of Eosinophilic Granulomatosis with Polyangiitis Treatments According to the Type of Manifestations Based on Analysis of 636 Patients* [354]

2. Irena Doubelt, *Efficacy of Conventional Immunosuppressants in Steroid-Dependent or Refractory Eosinophilic Granulomatosis with Polyangiitis: Study on a New Canadian Patient Cohort* [238]

3. Thomas Neumann, *Histology for Classification of Eosinophilic Granulomatosis with Polyangiitis* [106]

4. Benjamin Terrier, *Prediction of Long-Term Evolutionary Profiles in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) Based on Baseline and Follow-Up Characteristics* [117]

5. Emma Rubenstein, *Cluster Analysis to Explore Clinical Subclassification of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)* [162]

**Session M3B [Regency Ballroom]**  
**Behçet’s Syndrome**  
**Moderators:** Haner Direskeneli and Alfred Mahr

1. Fatma Alibaz-Oner, *Assessment of Femoral Vein Thickness with Doppler US Can Be a Diagnostic Tool for Behçet’s Disease* [063]


3. Mustafa Erdogan, *Factors Associated with Damage Progression in Behçet’s Syndrome Uveitis* [240]

4. Gülen Hatemi, *Improvements and Correlations in Oral Ulcers, Disease Activity, and QoL in Behçet’s Syndrome Patients Treated with Apremilast: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study* [249]

5. Maria Prasinou, *Alemtuzumab for the Treatment of Refractory Behçet’s Disease: A Subgroup Analysis from a Randomized, Prospective, Open Label, Dose Ranging Clinical Trial (NCT01405807). A Trial of Efficacy and Safety (ALEVIATE)* [335]

**3:00 – 3:15 BREAK [Millennium Hall]**

**3:15 – 5:30 POSTER SESSION 1 [Millennium Hall]**  
*Poster Presentations and Trainee Poster Tours 1*

**5:30 – 6:30 TRAINEE SESSION [Washington Room]**

**6:30 – 8:30 EARLY INVESTIGATORS NETWORKING DINNER [Howe on the 33rd Floor]**  
*Hosted by Rennie Rhee*
Tuesday, April 9, 2019

6:45 – 8:00  CONTINENTAL BREAKFAST  [Millennium Hall]

8:00 – 9:20  SESSION T1  [Regency Ballroom]
Innate Immunity and Potential Therapeutic Targets in ANCA-Associated Vasculitis
Moderators: Ronald Falk and Alan Salama
1. Marilina Antonelou, Therapeutic Myeloperoxidase Inhibition Attenuates Neutrophil Activation, ANCA-Mediated Endothelial Damage and Crescentic Glomerulonephritis [187]
2. Kim Maree O’Sullivan, Inhibition of Peptidylarginine Deiminase 4 Limits Neutrophil Extracellular Trap Formation and Inflammation in Experimental Anti MPO-ANCA Glomerulonephritis [209]
3. Anthony Rousselle, Classical Monocytes Promote Crescent Formation and Necrosis in ANCA-Associated Necrotizing Crescentic Glomerulonephritis [216]
4. Ralph Kettritz, Characterization of Cathepsin C as a Treatment Target in ANCA-Associated Vasculitis [196]
5. Maria Prendecki, Leucocyte Spleen Tyrosine Kinase in ANCA-Associated Vasculitis [213]

9:30 – 10:20  INVITED SPEAKER  [Regency Ballroom]
Moderator: Seza Özen
Rae S. M. Yeung MD, PhD, FRCPC
“Towards Precision Medicine – Lessons Learned from Kawasaki Disease”

10:20 – 11:00  BREAK AND POSTER VIEWING  [Millennium Hall]

11:00 – 12:20  BREAKOUTS

SESSION T2A  [Regency Ballroom]
Practical Biomarkers in Vasculitis
Moderators: Sarah Moran and Elisabeth Brouwer
1. Goksal Keskin, Interleukin-27 in Takayasu’s Arteritis: Serum Levels and Relationship with Disease Activity [021]
2. Ruchika Goel, Serum Biomarker Profile of Indian Patients with Takayasu’s Arteritis: Relation with Early and Late Angiographic Progression [012]
3. Laura Martinez Valenzuela, Utility of Measurements of Urinary Soluble Cd163 and Calprotectin in Assessing Disease Activity in ANCA-Associated Renal Vasculitis [009]
4. Sarah Moran, usCD163 is an Early Predictor of Treatment Response in Crescentic Glomerulonephritis [036]
5. Mostafa Mohrag, Urine Calprotectin as Disease Activity and Prognostic Biomarker in ANCA-Associated Vasculitis (AAV) [033]

SESSION T2B  [Commonwealth Hall A-D]
Imaging in Large-Vessel Vasculitis
Moderators: Tanaz Kermani and Justin Mason
1. Anne Haaverson, The Anteromedial Ultrasound Examination of the Large Supraaortic Vessels Identifies Higher Rates of Large Vessel Involvement than Previous Reported in Patients with Giant Cell Arteritis [085]
2. Kaitlin Quinn, Imaging Acquisition Technique Influences Interpretation of Positron Emission Tomography Vascular Activity in Large-Vessel Vasculitis [109]
3. Sema Kaymaz-Tahra, Can a One-Hour Quantitative Assessment of FDG-PET-CT (Modified-PETVAS) be Useful in Takayasu’s Arteritis? [257]
4. Roberto Padoan, Fully Integrated 18F-FDG PET/MR in Large Vessel Vasculitis [107]
5. Shubhasree Banerjee, Change in Vascular 18F-Fluorodeoxyglucose Positron Emission Tomography Activity with Treatment in Large Vessel Vasculitis in Relation to Clinical and Serologic Assessment [232]

12:30 – 1:30  SPONSORED LECTURE LUNCH  [Regency Ballroom]
OR LUNCH ON YOUR OWN
J. Charles Jennette, MD and Neil Basu, MD
“Improving Outcomes in AAV: What Are the Unmet Needs?”
Tuesday, April 9, 2019 (continued)

Session T3A
[Regency Ballroom]
Sub-Glottic Stenosis and Interstitial Lung Disease in ANCA-Associated Vasculitis
Moderators: Ulrich Specks and Luis Felipe Flores-Suárez
1. Kaitlin Quinn, Subglottic Stenosis and Endobronchial Disease in Granulomatosis with Polyangiitis [043]
2. Maria Camprodon Gómez, Tracheo-Bronchial Stenosis in Patients with Granulomatosis with Polyangiitis [289]
4. Luis Felipe Flores-Suárez, Differences in Lung High-Resolution Computed Tomography Findings Between Patients with Microscopic Polyangiitis and Interstitial Lung Disease, and Patients with MPO-ANCA Positive Interstitial Lung Disease [075]
5. Erina Tabata, Cystic Lesion in Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibody (MPO-ANCA)-Positive Interstitial Pneumonia: Radiological and Pathological Analysis [115]

Session T3B
[Commonwealth Hall A-B]
The Role of the Microbiome in Vasculitis
Moderators: Rennie Rhee and Sharon Chung
1. Alexandra Villa Forte, Microbiome in Aortitis [183]
2. Peter Lamprecht, Alterations of Diversity and Composition of the Upper Respiratory Tract Microbial Community in Granulomatosis with Polyangiitis [177]
3. Andreas Kronbichler, The Composition of the Human Nasal Microbiome in Granulomatosis with Polyangiitis: A Pilot Study [176]
4. Rennie Rhee, Longitudinal Changes in the Nasal Microbiome of Patients with Granulomatosis with Polyangiitis [180]
5. Kaori Tateyama, Does Bacterial or Viral Infection Play a Role in the Pathogenesis of Otitis Media with ANCA-Associated Vasculitis? [182]

Session T3C
[Commonwealth Hall C-D]
Clinical Epidemiology of Vasculitis
Moderators: Gunnar Tomasson and Joanna Robson
1. Arno Hessels, Geographic Differences in Clinical Presentation and Outcome of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Role of Antibody Specificity [144]
2. Jens Rathmann, Incidence and Predictors of Severe Infections in ANCA-Associated Vasculitis in a Population-Based Cohort – Preliminary Results [158]
3. Shifa Sarcia, Multi-Method Characterisation of Infection in ANCA-Associated Vasculitis: Results from a Longitudinal, Matched-Cohort Data Linkage Study [127]
5. Peter Merkel, Diagnostic Delays in Vasculitis and Factors Associated with Time to Diagnosis [122]
### Wednesday, April 10, 2019

#### 6:45 – 8:00
**Continental Breakfast** [Millennium Hall]

#### 8:00 – 9:20
**Session W1** [Regency Ballroom]
**Glucocorticoids and Plasma Exchange for Induction of Remission in ANCA-Associated Vasculitis: PEXIVAS and Beyond**

**Moderators:** Annette Bruchfeld and John Niles

3. Michael Walsh, *The Effect of Reduced-Dose Oral Glucocorticoids During Induction of Remission Induction in Severe ANCA-Associated Vasculitis* [361]
4. Michael Walsh, *The Effect of Plasma Exchange on End-Stage Renal Disease and Death in Patients with Severe ANCA-Associated Vasculitis* [360]

#### 9:20 – 10:40
**Session W2** [Regency Ballroom]
**Novel Therapies for Large-Vessel Vasculitis**

**Moderators:** Xinping Tian and Peter Grayson

2. Sebastian Unizony, *Risk Factors for Treatment Failure in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Versus Prednisone Alone* [358]
4. Maira Karabayas, *Stratified Glucocorticoid Monotherapy is Effective for Most Cases of Giant Cell Arteritis* [316]
5. Yoshikazu Nakaoka, *Long-Term Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis: Final Results from the TAKT Study* [332]

#### 10:40 – 11:00
**Break** [Millennium Hall]

#### 11:00 – 12:20
**Session W3** [Regency Ballroom]
**Treatment of Other Vasculitides**

**Moderators:** Xavier Puéchal and Aladdin Mohammad

1. Taryn Youngstein, *International Consensus Study on the Diagnosis and Management of Deficiency of Adenosine Deaminase 2 Vasculitis* [123]
3. Nikki Wong, *MEST-C Score in Adult Henoch-Schönlein Purpura Nephritis* [121]
5. Joop Aendekerk, *Severe Non-Infectious Mixed-Type Cryoglobulinemic Vasculitis: Long-Term Outcome During a Cyclophosphamide-Free Treatment Regimen* [276]

#### 12:20 – 12:30
**Closing Remarks/Wrap-Up** [Regency Ballroom]